RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM)

BACKGROUND: The mTOR pathway is frequently activated in patients with GBM and is associated with reduced survival, making this pathway a promising target. However, mTOR inhibitors, including everolimus and temsirolimus, have poor brain penetration, limiting their potential use for GBM. ABI-009 is a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Kesari, Santosh, Juarez, Tiffany, Carrillo, Jose, Truong, Judy, Nguyen, Minhdan, Heng, Annie, Gill, Jaya, Nguyen, Hanh, Nomura, Natsuko, Grigorian, Berta, Hou, Shihe, Schmid, Anita, Desai, Neil
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Randomized Brain Tumor Trials in Development
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847626/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.913
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items